KMID : 1022820160070010009
|
|
Journal of Multiple Sclerosis and Neuroimmunology 2016 Volume.7 No. 1 p.9 ~ p.13
|
|
Neutralizing Antibodies in Korean Multiple Sclerosis Patients Treated with Interferon-Beta: Preliminary Study
|
|
Hyun Hye-Sook
Kong Byung-Soo Joung Ae-Ran Jeong In-Hye Kim Su-Hyun Kim Ho-Jin
|
|
Abstract
|
|
|
Background: Patients treated with interferon-beta (IFN-¥â) can develop neutralizing antibodies (NAB) against IFN-¥â, which negatively affect its therapeutic responses. We aimed to investigate prevalence of NAB and to evaluate the impact of NAB on the treatment response of IFN-¥â in Korean patients with multiple sclerosis (MS).
Methods: This was a single center, retrospective study of MS patients treated with subcutaneous IFN-¥â-1a and IFN-¥â-1b in Korea. Patients with MS who were treated with IFN-¥â at least for 6 months were enrolled. Sera, which were not influenced by acute treatment for MS, were tested for NAB using the luciferase reporter gene assay.
Results: A total of 96 MS patients were enrolled. NAB were found in 28 (29%) patients at the single test; 23 of 66 (35%) patients treated with subcutaneous IFN-¥â-1b and 5 of 30 (17%) patients treated with subcutaneous IFN-¥â-1a. The frequency of NAB positivity was highest (n£½18, 39%) in patients treated with IFN-¥â for 12 to 24 months. Until now, 20 of 28 patients with NAB were tested at two different time points to confirm the persistent positivity of NAB. Of 20 patients with NAB at the single test, 11 patients showed persistent positivity of NAB and 8 of them (73%) revealed disease activity before and after 6 months of NAB positivity. In contrast, 3 of 9 patients (33%) who showed transient positivity of NAB showed disease activity.
Conclusions: The current study is ongoing to confirm the clinical implication of persistent positivity and titers of NAB in the multi-center cohort.
|
|
KEYWORD
|
|
Multiple sclerosis, Neutralizing antibody, Disease modifying treatment
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|